{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:54:56Z","timestamp":1793332496519,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Mitacs Accelerate Program","award":["IT08605"],"award-info":[{"award-number":["IT08605"]}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MSH-141980"],"award-info":[{"award-number":["MSH-141980"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000245","name":"Michael Smith Health Research BC","doi-asserted-by":"publisher","award":["16890"],"award-info":[{"award-number":["16890"]}],"id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nutr Metab (Lond)"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Substantial weight loss in people living with type 2 diabetes (T2D) can reduce the need for glucose-lowering medications while concurrently lowering glycemia below the diagnostic threshold for the disease. Furthermore, weight-loss interventions have also been demonstrated to improve aspects of underlying T2D pathophysiology related to ectopic fat in the liver and pancreatic beta-cell function. As such, the purpose of this secondary analysis was to explore the extent to which a low-carbohydrate and energy-restricted (LCER) diet intervention improves markers of beta-cell stress\/function, liver fat accumulation, and metabolic related liver function in people with type 2 diabetes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted secondary analyses of blood samples from a larger pragmatic community-based parallel-group randomized controlled trial involving a 12-week pharmacist implemented LCER diet (Pharm-TCR: &lt;50\u00a0g carbohydrates; ~850\u20131100\u00a0kcal\/day; <jats:italic>n<\/jats:italic>\u2009=\u200920) versus treatment-as-usual (TAU; <jats:italic>n<\/jats:italic>\u2009=\u200916). Participants were people with T2D, using\u2009\u2265\u20091 glucose-lowering medication, and a body mass index of \u2265\u200930\u00a0kg\/m<jats:sup>2<\/jats:sup>. Main outcomes were C-peptide to proinsulin ratio, circulating microRNA 375 (miR375), homeostatic model assessment (HOMA) beta-cell function (B), fatty liver index (FLI), hepatic steatosis index (HSI), HOMA insulin resistance (IR), and circulating fetuin-A and fibroblast growth factor 21 (FGF21). Data were analysed using linear regression with baseline as a covariate.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There was no observed change in miR375 (<jats:italic>p<\/jats:italic>\u2009=\u20090.42), C-peptide to proinsulin ratio (<jats:italic>p<\/jats:italic>\u2009=\u20090.17) or HOMA B (<jats:italic>p<\/jats:italic>\u2009=\u20090.15). FLI and HSI were reduced by -25.1 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) and \u2212\u20094.9 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), respectively. HOMA IR was reduced by -46.5% (<jats:italic>p<\/jats:italic>\u2009=\u20090.011). FGF21 was reduced by -161.2pg\/mL (<jats:italic>p<\/jats:italic>\u2009=\u20090.035) with a similar tendency found for fetuin-A (mean difference: -16.7ng\/mL; <jats:italic>p<\/jats:italic>\u2009=\u20090.11). These improvements in markers of hepatic function were accompanied by reductions in circulating metabolites linked to hepatic insulin resistance (e.g., diacylglycerols, ceramides) in the Pharm TCR group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The Pharm-TCR intervention did not improve fasting indices of beta-cell stress; however, markers of liver fat accumulation and and liver function were improved, suggesting that a LCER diet can improve some aspects of the underlying pathophysiology of T2D.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Clinicaltrials.gov (NCT03181165).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12986-024-00807-x","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T03:16:13Z","timestamp":1716779773000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A secondary analysis of indices of hepatic and beta cell function following 12 weeks of carbohydrate and energy restriction vs. free-living control in adults with type 2 diabetes"],"prefix":"10.1186","volume":"21","author":[{"given":"Cody","family":"Durrer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hashim","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoning Howard","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Dolores Moya","family":"Garzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuchao","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"McKelvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan M.","family":"Batterham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan Z.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan P.","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,27]]},"reference":[{"key":"807_CR1","unstructured":"International Diabetes Federation. IDF Diabetes Atlas, 9th edn [Internet]. Brussels, Belgium. 2019. https:\/\/www.diabetesatlas.org."},{"key":"807_CR2","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3389\/fendo.2019.00348","volume":"10","author":"SJ Athinarayanan","year":"2019","unstructured":"Athinarayanan SJ, Adams RN, Hallberg SJ, McKenzie AL, Bhanpuri NH, Campbell WW, et al. Long-Term Effects of a Novel Continuous Remote Care Intervention Including Nutritional Ketosis for the Management of Type 2 Diabetes: A 2-Year Non-randomized Clinical Trial. Front Endocrinol. 2019;10:348.\u00a0http:\/\/www.frontiersin.org\/Endocrinology.","journal-title":"Front Endocrinol"},{"issue":"5","key":"807_CR3","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S2213-8587(19)30068-3","volume":"7","author":"MEJ Lean","year":"2019","unstructured":"Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol. 2019;7(5):344\u201355. https:\/\/doi.org\/10.1016\/S2213-8587(19)30068-3.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"807_CR4","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1007\/s00125-011-2204-7","volume":"54","author":"EL Lim","year":"2011","unstructured":"Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia [Internet]. 2011;54(10):2506\u201314. Available from: https:\/\/doi.org\/10.1007\/s00125-011-2204-7.","journal-title":"Diabetologia [Internet]"},{"issue":"4","key":"807_CR5","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.cmet.2018.07.003","volume":"28","author":"R Taylor","year":"2018","unstructured":"Taylor R, Al-Mrabeh A, Zhyzhneuskaya S, Peters C, Barnes AC, Aribisala BS, et al. Remission of Human Type 2 Diabetes Requires Decrease in Liver and Pancreas Fat Content but Is Dependent upon Capacity for \u03b2 Cell Recovery. Cell Metab. 2018;28(4):547-556.e3.\u00a0http:\/\/ovidsp.ovid.com\/ovidweb.cgi?T=JS&PAGE=reference&D=med15&NEWS=N&AN=30078554.","journal-title":"Cell Metab"},{"issue":"6","key":"807_CR6","doi-asserted-by":"publisher","first-page":"403","DOI":"10.7326\/0003-4819-142-6-200503150-00006","volume":"142","author":"G Boden","year":"2005","unstructured":"Boden G, Sargrad K, Homko C, Mozzoli M, Stein TP. Effect of a Low-Carbohydrate Diet on Appetite, Blood Glucose Levels, and Insulin Resistance in Obese Patients with Type 2 Diabetes. Ann Intern Med. 2005;142(6):403.\u00a0http:\/\/annals.org\/aim\/fullarticle\/718265.","journal-title":"Ann Intern Med"},{"issue":"1","key":"807_CR7","first-page":"E7\u201318","volume":"320","author":"MJ Skytte","year":"2021","unstructured":"Skytte MJ, Samkani A, Astrup A, Frystyk J, Rehfeld JF, Holst JJ, et al. Effects of carbohydrate restriction on postprandial glucose metabolism, \u03b2 -cell function, gut hormone secretion, and satiety in patients with Type 2 diabetes. Am J Physiol Metab. 2021;320(1):E7-18.\u00a0http:\/\/ovidsp.ovid.com\/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=33103448.","journal-title":"Am J Physiol Metab"},{"issue":"11","key":"807_CR8","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.2337\/dc09-9036","volume":"32","author":"JB Buse","year":"2009","unstructured":"Buse JB, Caprio S, Cefalu WT, Ceriello A, Prato Del S, Inzucchi SE, et al. How Do We Define Cure of Diabetes? Diabetes Care. 2009;32(11):2133\u20135.\u00a0http:\/\/care.diabetesjournals.org\/content\/diacare\/32\/11\/2133.full.pdf.","journal-title":"Diabetes Care"},{"issue":"6","key":"807_CR9","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/j.1464-5491.2011.03306.x","volume":"28","author":"JB Dixon","year":"2011","unstructured":"Dixon JB, Zimmet P, Alberti KG, Rubino F. Bariatric surgery: an IDF statement for obese Type 2 diabetes. Diabet Med. 2011;28(6):628\u201342.\u00a0http:\/\/ubc.summon.serialssolutions.com\/2.0.0\/link\/0\/eLvHCXMwtV1LS8NAEF6qRRFEtCq-2ZOXkJIm220qeKit9QEiaL30EprsBgptKraF_nxnH8kmRdQKXkLZ0mmS-fh2ZvebWYQ8t-rYS5zgelHIQ4dEjZhRP3ToIKqHJIwo8xqRF5OiVKeUnpZmxv7V8TAGrheFtCs4PzMKA_AZIABXAAFcfwWDG8iFZRd-a6oKoGV1c2I9dLq.","journal-title":"Diabet Med"},{"issue":"2","key":"807_CR10","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s00125-012-2762-3","volume":"56","author":"DL Eizirik","year":"2013","unstructured":"Eizirik DL, Miani M, Cardozo AK. Signalling danger: endoplasmic reticulum stress and the unfolded protein response in pancreatic islet inflammation. Diabetologia. 2013;56(2):234\u201341.\u00a0http:\/\/link.springer.com\/10.1007\/s00125-012-2762-3.","journal-title":"Diabetologia"},{"issue":"1","key":"807_CR11","doi-asserted-by":"publisher","first-page":"bqac184","DOI":"10.1210\/endocr\/bqac184","volume":"164","author":"A Kulkarni","year":"2022","unstructured":"Kulkarni A, Muralidharan C, May SC, Tersey SA, Mirmira RG. Inside the \u03b2 Cell: Molecular Stress Response Pathways in Diabetes Pathogenesis. Endocrinology. 2022;164(1):bqac184.\u00a0https:\/\/academic.oup.com\/endo\/article\/doi\/10.1210\/endocr\/bqac184\/6783239.","journal-title":"Endocrinology"},{"issue":"4","key":"807_CR12","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Golabi P, Avila de L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol. 2019;71(4):793\u2013801. https:\/\/doi.org\/10.1016\/j.jhep.2019.06.021.","journal-title":"J Hepatol"},{"issue":"9","key":"807_CR13","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nrendo.2017.56","volume":"13","author":"RCR Meex","year":"2017","unstructured":"Meex RCR, Watt MJ. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat Rev Endocrinol. 2017;13(9):509\u201320. https:\/\/doi.org\/10.1038\/nrendo.2017.56.","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"807_CR14","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/j.1365-2265.2011.04070.x","volume":"75","author":"H Ou","year":"2011","unstructured":"Ou H, Yang Y, Wu H, Wu J, Lu F, Chang C. Serum fetuin-A concentrations are elevated in subjects with impaired glucose tolerance and newly diagnosed type 2 diabetes. Clin Endocrinol (Oxf). 2011;75(4):450\u20135.\u00a0https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1111\/j.1365-2265.2011.04070.x.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"807_CR15","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1093\/ajcn\/nqy261","volume":"109","author":"CR Chang","year":"2019","unstructured":"Chang CR, Francois ME, Little JP. Restricting carbohydrates at breakfast is sufficient to reduce 24-hour exposure to postprandial hyperglycemia and improve glycemic variability. Am J Clin Nutr. 2019;109(5):1302\u20139.\u00a0https:\/\/academic.oup.com\/ajcn\/article\/109\/5\/1302\/5435774.","journal-title":"Am J Clin Nutr."},{"issue":"1","key":"807_CR16","doi-asserted-by":"publisher","first-page":"H105","DOI":"10.1152\/ajpheart.00524.2017","volume":"314","author":"ME Francois","year":"2018","unstructured":"Francois ME, Myette-Cote E, Bammert TD, Durrer C, Neudorf H, DeSouza CA, et al. Carbohydrate restriction with postmeal walking effectively mitigates postprandial hyperglycemia and improves endothelial function in type 2 diabetes. Am J Physiol Circ Physiol. 2018;314(1):H105\u201313.","journal-title":"Am J Physiol Circ Physiol"},{"issue":"1","key":"807_CR17","doi-asserted-by":"publisher","first-page":"5367","DOI":"10.1038\/s41467-021-25667-4","volume":"12","author":"C Durrer","year":"2021","unstructured":"Durrer C, McKelvey S, Singer J, Batterham AM, Johnson JD, Gudmundson K, et al. A randomized controlled trial of pharmacist-led therapeutic carbohydrate and energy restriction in type 2 diabetes. Nat Commun. 2021;12(1):5367. https:\/\/doi.org\/10.1038\/s41467-021-25667-4.","journal-title":"Nat Commun."},{"issue":"1","key":"807_CR18","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1186\/s13063-019-3873-7","volume":"20","author":"C Durrer","year":"2019","unstructured":"Durrer C, McKelvey S, Singer J, Batterham AM, Johnson JD, Wortman J, et al. Pharmacist-led therapeutic carbohydrate restriction as a treatment strategy for type 2 diabetes: the Pharm-TCR randomized controlled trial protocol. Trials. 2019;20(1):781.\u00a0https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-019-3873-7.","journal-title":"Trials"},{"issue":"1","key":"807_CR19","doi-asserted-by":"publisher","first-page":"160","DOI":"10.4103\/2230-8210.146874","volume":"19","author":"M Gutch","year":"2015","unstructured":"Gutch M, Kumar S, Razi SM, Gupta KK, Gupta A. Assessment of insulin sensitivity\/resistance. Indian J Endocrinol Metab. 2015;19(1):160.","journal-title":"Indian J Endocrinol Metab"},{"issue":"6","key":"807_CR20","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.2337\/diacare.27.6.1487","volume":"27","author":"TM Wallace","year":"2004","unstructured":"Wallace TM, Levy JC, Matthews DR. Use and Abuse of HOMA Modeling. Diabetes Care. 2004;27(6):1487\u201395.\u00a0http:\/\/care.diabetesjournals.org\/content\/27\/6\/1487.abstract.","journal-title":"Diabetes Care"},{"issue":"1","key":"807_CR21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-230X-6-33","volume":"6","author":"G Bedogni","year":"2006","unstructured":"Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6(1):33. https:\/\/doi.org\/10.1186\/1471-230X-6-33.","journal-title":"BMC Gastroenterol"},{"issue":"7","key":"807_CR22","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","volume":"42","author":"J-H Lee","year":"2010","unstructured":"Lee J-H, Kim D, Kim HJ, Lee C-H, Yang JI, Kim W, et al. Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42(7):503\u20138 https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1590865809003363.","journal-title":"Dig Liver Dis"},{"key":"807_CR23","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing [Internet]. Vienna, Austria. 2021. https:\/\/www.r-project.org\/."},{"key":"807_CR24","unstructured":"Lenth Remmeans. Estimated Marginal Means, aka Least-Squares Means [Internet]. 2020. https:\/\/cran.r-project.org\/package=emmeans."},{"issue":"18","key":"807_CR25","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","volume":"32","author":"Z Gu","year":"2016","unstructured":"Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 2016;32(18):2847\u20139.\u00a0https:\/\/academic.oup.com\/bioinformatics\/article\/32\/18\/2847\/1743594.","journal-title":"Bioinformatics"},{"issue":"1","key":"807_CR26","doi-asserted-by":"publisher","first-page":"e86","DOI":"10.1002\/cpbi.86","volume":"68","author":"J Chong","year":"2019","unstructured":"Chong J, Wishart DS, Xia J. Using MetaboAnalyst 4.0 for comprehensive and integrative metabolomics data analysis. Curr Protoc Bioinforma. 2019;68(1):e86.","journal-title":"Curr Protoc Bioinforma"},{"issue":"11","key":"807_CR27","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.2337\/db18-0279","volume":"67","author":"T Mezza","year":"2018","unstructured":"Mezza T, Ferraro PM, Sun VA, Moffa S, Cefalo CMA, Quero G, et al. Increased \u03b2-Cell Workload Modulates Proinsulin-to-Insulin Ratio in Humans. Diabetes. 2018;67(11):2389\u201396.\u00a0http:\/\/diabetes.diabetesjournals.org\/lookup\/doi\/10.2337\/db18-0279.","journal-title":"Diabetes"},{"issue":"12","key":"807_CR28","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.3390\/cells8121533","volume":"8","author":"S Vasu","year":"2019","unstructured":"Vasu S, Kumano K, Darden CM, Rahman I, Lawrence MC, Naziruddin B. MicroRNA Signatures as Future Biomarkers for Diagnosis of Diabetes States. Cells. 2019;8(12):1533.\u00a0https:\/\/www.mdpi.com\/2073-4409\/8\/12\/1533.","journal-title":"Cells"},{"issue":"10","key":"807_CR29","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11892-016-0783-x","volume":"16","author":"RG Mirmira","year":"2016","unstructured":"Mirmira RG, Sims EK, Syed F, Evans-Molina C. Biomarkers of \u03b2-Cell Stress and Death in Type 1 Diabetes. Curr Diab Rep. 2016;16(10):95.\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/27541297.","journal-title":"Curr Diab Rep"},{"issue":"1","key":"807_CR30","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1210\/jc.2004-0699","volume":"90","author":"K Maedler","year":"2005","unstructured":"Maedler K, Carr RD, BoscO D, Zuellig RA, BerneY T, DonatH MY. Donath MY. Sulfonylurea induced \u03b2-cell apoptosis in cultured human islets. J Clin Endocrinol Metab [Internet]. 2005;90(1):501\u20136. https:\/\/doi.org\/10.1210\/jc.2004-0699.","journal-title":"J Clin Endocrinol Metab [Internet]"},{"issue":"12","key":"807_CR31","doi-asserted-by":"publisher","first-page":"4057","DOI":"10.2337\/db14-0595","volume":"63","author":"KR Markan","year":"2014","unstructured":"Markan KR, Naber MC, Ameka MK, Anderegg MD, Mangelsdorf DJ, Kliewer SA, et al. Circulating FGF21 Is Liver Derived and Enhances Glucose Uptake During Refeeding and Overfeeding. Diabetes. 2014;63(12):4057\u201363.\u00a0http:\/\/diabetes.diabetesjournals.org\/cgi\/doi\/10.2337\/db14-0595.","journal-title":"Diabetes"},{"issue":"8","key":"807_CR32","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.2337\/dc09-0684","volume":"32","author":"AO Chavez","year":"2009","unstructured":"Chavez AO, Molina-Carrion M, Abdul-Ghani MA, Folli F, DeFronzo RA, Tripathy D. Circulating Fibroblast Growth Factor-21 Is Elevated in Impaired Glucose Tolerance and Type 2 Diabetes and Correlates With Muscle and Hepatic Insulin Resistance. Diabetes Care. 2009;32(8):1542\u20136.\u00a0http:\/\/care.diabetesjournals.org\/cgi\/doi\/10.2337\/dc09-0684.","journal-title":"Diabetes Care"},{"issue":"7","key":"807_CR33","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1210\/jc.2016-1681","volume":"101","author":"JS Hansen","year":"2016","unstructured":"Hansen JS, Pedersen BK, Xu G, Lehmann R, Weigert C, Plomgaard P. Exercise-Induced Secretion of FGF21 and Follistatin Are Blocked by Pancreatic Clamp and Impaired in Type 2 Diabetes. J Clin Endocrinol Metab. 2016;101(7):2816\u201325.\u00a0https:\/\/www.semanticscholar.org\/paper\/3417f8ab018605064db4d13be11008ba3d3b3fe1.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"807_CR34","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1038\/nm.2851","volume":"18","author":"D Pal","year":"2012","unstructured":"Pal D, Dasgupta S, Kundu R, Maitra S, Das G, Mukhopadhyay S, et al. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med. 2012;18(8):1279\u201385.\u00a0https:\/\/www-nature-com.ep.fjernadgang.kb.dk\/articles\/nm.2851.","journal-title":"Nat Med"},{"issue":"7","key":"807_CR35","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.tips.2017.04.004","volume":"38","author":"MC Petersen","year":"2017","unstructured":"Petersen MC, Shulman GI. Roles of Diacylglycerols and Ceramides in Hepatic Insulin Resistance. Trends Pharmacol Sci. 2017;38(7):649\u201365.\u00a0https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614717300962.","journal-title":"Trends Pharmacol Sci"},{"issue":"4","key":"807_CR36","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.2337\/dc21-1705","volume":"45","author":"J Morze","year":"2022","unstructured":"Morze J, Wittenbecher C, Schwingshackl L, Danielewicz A, Rynkiewicz A, Hu FB, et al. Metabolomics and Type 2 Diabetes Risk: An Updated Systematic Review and Meta-analysis of Prospective Cohort Studies. Diabetes Care. 2022;45(4):1013\u201324.\u00a0https:\/\/diabetesjournals.org\/care\/article\/45\/4\/1013\/144892\/Metabolomics-and-Type-2-Diabetes-Risk-An-Updated.","journal-title":"Diabetes Care"},{"issue":"5","key":"807_CR37","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.2337\/db12-0707","volume":"62","author":"E Ferrannini","year":"2013","unstructured":"Ferrannini E, Natali A, Camastra S, Nannipieri M, Mari A, Adam K-P, et al. Early Metabolic Markers of the Development of Dysglycemia and Type 2 Diabetes and Their Physiological Significance. Diabetes. 2013;62(5):1730\u20137.\u00a0https:\/\/diabetesjournals.org\/diabetes\/article\/62\/5\/1730\/42895\/Early-Metabolic-Markers-of-the-Development-of.","journal-title":"Diabetes"}],"container-title":["Nutrition &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12986-024-00807-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12986-024-00807-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12986-024-00807-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T03:19:47Z","timestamp":1716779987000},"score":1,"resource":{"primary":{"URL":"https:\/\/nutritionandmetabolism.biomedcentral.com\/articles\/10.1186\/s12986-024-00807-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,27]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["807"],"URL":"https:\/\/doi.org\/10.1186\/s12986-024-00807-x","relation":{},"ISSN":["1743-7075"],"issn-type":[{"value":"1743-7075","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,27]]},"assertion":[{"value":"14 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.P.L. holds founder shares and advises for Metabolic Insights Inc., and is volunteer Chief Scientific Officer for the not-for-profit Institute for Personalized Therapeutic Nutrition. S.M. is employed as Chief Executive Officer for the not-for-profit Institute for Personalized Therapeutic Nutrition. J.D.J. is Chair of the Board for the Institute for Personalized Therapeutic Nutrition and receives no compensation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29"}}